English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We performed a randomized and placebo-controlled clinical study to investigate whether nab -paclitaxel can improve survival in patients with advanced non-small cell lung cancer (NSCLC) after unsuccessful first-line chemotherapy. Patients with stages III to IV advanced NSCLC after first-line platinum-based chemotherapy failure were randomly assigned in a 1:1 ratio to receive second-line treatment of nab -paclitaxel or placebo. Ninety two eligible patients were enrolled in the study. The median progression-free survival (PFS) was 4.6 months (95% confidence interval (CI): 3.4-6.7 months) for nab -paclitaxel, compared with 2.0 months (95% CI: 0.9-4.3 months) for placebo, representing a 56% reduction in disease progression (hazard ratio: 0.62; 95% CI: 0.33-0.81; P &lt;0.001). The median overall survival (OS) was 6.3 months (95% CI: 3.9-8.2 months) for nab -paclitaxel, compared with 4.9 months (95% CI: 2.1-5.9 months) for placebo, representing a 22% reduction in disease progression (hazard ratio: 0.71; 95% CI: 0.33-0.85; P &lt;0.001). Adverse events (AEs) were also observed for nab -paclitaxel. Nab -paclitaxel can improve survival in patients with advanced NSCLC after unsuccessful first-line chemotherapy.

bioscience reports

A randomized placebo-controlled clinical study of <i>nab</i>-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China

A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China